Compare Check Point Software Technologies Ltd (CHKP) vs Eli Lilly And Co (LLY) Price & Performance

Check Point Software (CHKP) trades at $127.61, down 2.69% amid bearish technical signals, though it maintains strong fundamentals with a 37.93% net margin and consistent earnings beats. The company shows robust profitability with 86.12% gross margins and positive cash flow generation of $1.29B in 2025. Recent news highlights AI security growth potential and insider selling activity.

The stock presents a value opportunity with a 13.24 P/E ratio below industry averages, supported by analyst consensus target of $146.92 representing 15% upside. Key risks include competitive pressures in cybersecurity and margin compression trends. Institutional sentiment remains mixed with 41% buy ratings versus 51% hold recommendations.

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.